| 英文名稱 | Asperosaponin Ⅵ |
|---|---|
| 中文名稱 | 川續斷皂苷VI/木通皂苷D/木通皂甙D/川續斷皂苷Ⅵ |
| CAS號 | 39524-08-8 |
| 分子式 | C47H76O18 |
| 分子量 | 929.10 |
| 外觀 | 白色粉末 |
| 熔點 | 234-235 °C |
| 沸點 | 990.2±65.0 °C | Condition: Press: 760 Torr |
| 酸度系數pKa | 12.50±0.70 | Condition: Most Acidic Temp: 25 °C |
| 英文名稱 | Asperosaponin Ⅵ |
|---|---|
| 中文名稱 | 川續斷皂苷VI/木通皂苷D/木通皂甙D/川續斷皂苷Ⅵ |
| CAS號 | 39524-08-8 |
| 分子式 | C47H76O18 |
| 分子量 | 929.10 |
| 外觀 | 白色粉末 |
| 熔點 | 234-235 °C |
| 沸點 | 990.2±65.0 °C | Condition: Press: 760 Torr |
| 酸度系數pKa | 12.50±0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0000133
中文名稱：川續斷皂苷VI
中文別名：木通皂苷D；木通皂甙D；川續斷皂苷Ⅵ
英文名稱：Asperosaponin Ⅵ
英文別名：3-O-α-L-Arabinopyranosylhederagenin 28-O-β-D-glucopyranosyl-(1→6)-β-D-glucopyranoside;Akebia saponin D;Asperosaponin VI;Hederagenin 3-O-α-L-arabinopyranosyl-28-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside;Leiyemudanoside A;Tauroside St-G0-1;
分子式：C47H76O18
分子量：929.10
CAS號：39524-08-8
純度：HPLC≥98%
熔點：234-235 °C
沸點：990.2±65.0 °C | Condition: Press: 760 Torr
密度：1.43±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數：12.50±0.70 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規格：5mg10mg20mg50mg100mg500mg1g2g等應客戶需求包裝
供應單位：四川省維克奇生物科技有限公司
供應電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產中藥類標準品和天然植物有效單體，主打中藥對照品/標準品/天然植物有效單體，化學合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關注！ 新批次有現貨，歡迎咨詢。
| Comparative pharmacokinetic analysis of extracts of crude and wine-processed Dipsacus asper in rats by a sensitive ultra performance liquid chromatography–tandem mass spectrometry approach | ||
| 來源：SCI：JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 作者：Yi Tao | 備注：影響因子：2.687 |
| 引用描述 | ||
4-Caffeoylquinic acid(4-CQA), chlorogenic acid(3-CQA), 3,5-dicaffeoylquinic acid(3,5-diCQA), loganic acid, loganin, sweroside, dipsacoside B and asperosaponin VI were purchased from Sichuan Weikeqi Biotechnology Co. Chloramphenicol and glycyrrhetinic acid were purchased from Shanghai Yuanye Biological Technology Co. | ||
| Integrating UHPLC–MS/MS quantification and DAS analysis to investigate the effects of wine-processing on the tissue distributions of bioactive constituents of herbs in rats: Exemplarily shown for Dipsacus asper | ||
| 來源：SCI：JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 作者：Yi Tao | 備注：影響因子：2.603 |
| 引用描述 | ||
authenticated by Prof.Cai Baochang, Director of Jiangsu Key Laboratory of Chinese Medicine Processing, Nanjing University of Chinese Medicine. Standard substances were purchased from Sichuan Weikeqi Biotechnology Co located in Chengdu City, Sichuan Province, including 4-caffeoylquinic acid (4-CQA), chlorogenic acid (3-CQA), 3,5-dicaffeoylquinic acid (3,5-diCQA), loganic acid, loganin, and asperosaponin VI. | ||
| UHPLC–MS/MS quantification combined with chemometrics for the comparative analysis of different batches of raw and wine-processed Dipsacus asper | ||
| 來源：SCI：JOURNAL OF SEPARATION SCIENCE | 作者：Yi Tao | 備注：影響因子：2.557 |
| 引用描述 | ||
Standard compounds, including 4-caffeoylquinic acid (4-CQA), chlorogenic acid (3-CQA), 3,5-dicaffeoylquinic acid (3,5-diCQA), loganic acid, loganin, sweroside, dipsacoside B, and asperosaponin VI were purchased from Sichuan Weikeqi Biotechnology. Chloramphenicol and glycyrrhetinic acid were obtained from Shanghai Yuanye Biological Technology. The purity of each standard substance was more than 98%. HPLC-grade acetonitrile was obtained from Merck. | ||
| Simultaneous Determination of Ten Bioactive Components in Raw and Processed Radix Dipsaci by UPLC-Q-TOF-MS | ||
| 來源：SCI：JOURNAL OF CHROMATOGRAPHIC SCIENCE | 作者：Tao Yi | 備注：影響因子：1.216 |
| 引用描述 | ||
Standard substances, including 4-caffeoylquinic acid (4-CQA), loganic acid, 3,4-dicaffeoylquinic acid (3,4-diCQA), 3,5-dicaffeoylquinic acid (3,5-diCQA), loganin, sweroside and asperosaponin VI were purchased from Sichuan Weikeqi Biotechnology Co. Dipsacussaponin B, asperosaponin V and dipsacoside A were obtained from Nanjing Shizhou Biological Technology Co. The purity of each standard substance was >98%. Their chemical structures are shown in Supplementary Figure S1. | ||
